These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 8011552)
1. Severe cytopenias associated with the sequential use of busulphan and interferon-alpha in chronic myeloid leukaemia. Shepherd PC; Richards S; Allan NC Br J Haematol; 1994 Jan; 86(1):92-6. PubMed ID: 8011552 [TBL] [Abstract][Full Text] [Related]
2. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Hehlmann R; Heimpel H; Hasford J; Kolb HJ; Pralle H; Hossfeld DK; Queisser W; Löffler H; Hochhaus A; Heinze B Blood; 1994 Dec; 84(12):4064-77. PubMed ID: 7994025 [TBL] [Abstract][Full Text] [Related]
3. Successful treatment of accelerated and blastic phase of chronic myeloid leukemia with high-dose interferon alpha and hydroxyurea: a novel approach. Jehn U; Pötscher C; Heinemann V Leuk Lymphoma; 1995 Sep; 19(1-2):153-7. PubMed ID: 8574162 [TBL] [Abstract][Full Text] [Related]
4. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Silver RT; Woolf SH; Hehlmann R; Appelbaum FR; Anderson J; Bennett C; Goldman JM; Guilhot F; Kantarjian HM; Lichtin AE; Talpaz M; Tura S Blood; 1999 Sep; 94(5):1517-36. PubMed ID: 10477676 [TBL] [Abstract][Full Text] [Related]
5. The maintenance of busulphan-induced remissions in chronic granulocytic leukaemia with recombinant interferon alpha-2b. Bergsagel DE; Messner H Br J Cancer; 1990 Jun; 61(6):895-8. PubMed ID: 2372493 [TBL] [Abstract][Full Text] [Related]
6. [Treatment with interferon alfa-2a in the chronic phase of Philadelphia-positive chronic myeloid leukemia]. Steegmann JL; Lavilla E; Somolinos N; Pérez-Sánchez M; Lamana M; Olmeda F; Cámara R; Arranz R; Ferro MT; Fernández-Rañada JM Sangre (Barc); 1992 Oct; 37(5):375-81. PubMed ID: 1293778 [TBL] [Abstract][Full Text] [Related]
7. The German CML study, comparison of busulfan vs. hydroxyurea vs. interferon alpha and establishment of prognostic score 1. Hehlmann R; Heimpel H; Kolb HJ; Heinze B; Hochhaus A; Griesshammer M; Pralle H; Queisser WP; Essers U; Falge C Leuk Lymphoma; 1993; 11 Suppl 1():159-68. PubMed ID: 8251890 [TBL] [Abstract][Full Text] [Related]
8. A prospective comparison of alpha-IFN and conventional chemotherapy in Ph+ chronic myeloid leukemia. Clinical and cytogenetic results at 2 years in 322 patients. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Haematologica; 1992; 77(3):204-14. PubMed ID: 1427426 [TBL] [Abstract][Full Text] [Related]
9. [Complete cytogenetic remission of chronic myeloid leukemia with low-dose interferon alfa-2b and monthly high-dose busulfan]. Armenta D; Espallargas C; Paz A; Rodríguez Martorel J; Ladines R; Alvarez C; Román J; Andrés P Sangre (Barc); 1996 Dec; 41(6):465-7. PubMed ID: 9148424 [TBL] [Abstract][Full Text] [Related]
10. [Therapy of chronic myeloid leukemia with interferon, alone or combined. Preliminary experience]. Nese M Sangre (Barc); 1991 Oct; 36(5):419-22. PubMed ID: 1816638 [TBL] [Abstract][Full Text] [Related]
11. Treatment of chronic myeloid leukemia with interferon alpha (Roferon): results of the Israeli Study Group on CML. Shtalrid M; Lugassy G; Rosensaft J; Berrebi A Leuk Lymphoma; 1993; 11 Suppl 1():193-7. PubMed ID: 8251895 [TBL] [Abstract][Full Text] [Related]
12. Hydroxyurea versus busulphan for chronic myeloid leukaemia: an individual patient data meta-analysis of three randomized trials. Chronic myeloid leukemia trialists' collaborative group. Br J Haematol; 2000 Sep; 110(3):573-6. PubMed ID: 10997966 [TBL] [Abstract][Full Text] [Related]
13. [Interferon-alpha in the treatment of patients with chronic myeloid leukemia]. Faber E; Jarosová M; Divoký V; Luhový M; Komenda S; Sulovská I; Hubácek J; Slezák P; Papajik T; Raida L; Heczko M; Indrák K Vnitr Lek; 1997 Jan; 43(1):13-7. PubMed ID: 9221559 [TBL] [Abstract][Full Text] [Related]
14. [The assessment of therapeutic success in chronic myeloid leukemia]. Griesshammer M; Hehlmann R; Heimpel H Dtsch Med Wochenschr; 1995 Apr; 120(17):620-5. PubMed ID: 7537652 [No Abstract] [Full Text] [Related]
15. Progress with interferon in CML--results of the MRC UK CML III study. Shepherd PC; Richards SM; Allan NC Bone Marrow Transplant; 1996 May; 17 Suppl 3():S15-8. PubMed ID: 8769693 [TBL] [Abstract][Full Text] [Related]
16. Autoimmune mediated thrombocytopenia associated with the use of interferon-alpha in chronic myeloid leukemia. Zuffa E; Vianelli N; Martinelli G; Tazzari P; Cavo M; Tura S Haematologica; 1996; 81(6):533-5. PubMed ID: 9009441 [TBL] [Abstract][Full Text] [Related]
18. Marrow aplasia developing 3 years after treatment with busulphan for chronic myeloid leukaemia. Bowcock SJ; Galton DA; Goldman JM Eur J Haematol; 1989 May; 42(5):496-7. PubMed ID: 2567249 [TBL] [Abstract][Full Text] [Related]
19. Recombinant human erythropoietin at high doses stimulates thrombopoiesis: treatment for protracted severe myelosuppression complicating interferon-alpha and busulfan therapy for chronic myelogenous leukaemia. Kitagawa S; Saito M; Miura Y Eur J Haematol; 1995 Oct; 55(4):285-6. PubMed ID: 7589353 [No Abstract] [Full Text] [Related]
20. Busulphan and melphalan prior to autologous transplantation for myeloid malignancies. Cony-Makhoul P; Marit G; Boiron JM; Puntous M; Reiffers J Bone Marrow Transplant; 1995 Jul; 16(1):69-70. PubMed ID: 7581131 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]